Metex (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This inhibition reduces the synthesis of DNA, RNA and proteins, especially in rapidly dividing cells. Additionally, methotrexate raises extracellular adenosine levels, producing anti‑inflammatory effects that help manage autoimmune disorders.

The dose of Metex is individualized by the prescribing healthcare professional based on the specific indication, disease severity, patient weight, renal and hepatic function, and concurrent therapies. Only a qualified prescriber can set the appropriate dosing regimen; patients should follow the written prescription without alteration.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated in pregnancy because of a high risk of fetal malformations and miscarriage. It is also not recommended during breastfeeding, as it can be excreted in milk and affect the infant. Effective contraception is required for women of child‑bearing potential.

To request Metex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifying trade or institutional credentials before providing a formal quotation, availability details, shipping terms (including cold‑chain where applicable) and necessary import documentation.

Compared with biologic DMARDs, methotrexate (Metex) is a small‑molecule antimetabolite that can be administered orally or by injection and is generally less expensive. It has a well‑established efficacy profile for rheumatoid arthritis and psoriasis, but may require more laboratory monitoring for hepatic and marrow toxicity than some newer agents.

Metex should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature for a short period during administration, it may be used, but it should be returned to refrigeration promptly.

Metex is supplied as a sterile solution for injection and can be given intramuscularly, intravenously or subcutaneously, depending on the clinical indication and prescriber preference. The injection is performed by a qualified healthcare professional using aseptic technique, and the site of administration is chosen according to the prescribed route.

The most serious adverse events include severe liver toxicity (fibrosis or cirrhosis), pulmonary fibrosis or interstitial pneumonitis, renal failure, and profound bone‑marrow suppression leading to pancytopenia. These risks require regular laboratory monitoring and immediate medical attention if symptoms such as persistent cough, jaundice, or unexplained infections develop.

Metex is contraindicated in pregnant or breastfeeding women, patients with known hypersensitivity to methotrexate, and individuals with severe hepatic or renal impairment. It should also be avoided in patients with active infections or uncontrolled immunodeficiency until the underlying condition is stabilized.